Drug Profile
Research programme: cachexia therapeutic - Endevica Bio
Latest Information Update: 03 Feb 2023
Price :
$50
*
At a glance
- Originator Tensive Controls
- Developer Endevica Bio
- Class Melanocortins; Peptides
- Mechanism of Action Melanocortin receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cachexia